Agios second shot at sickle cell disease falls short on July 22, 2026 Agios Pharmaceuticals Anemia, Sickle Cell Decision development aspects discontinued mitapivat PK activator PYRUKYND tebapivat United States Food and Drug Administration +
Taking the temperature on new and emerging SCD therapies on May 19, 2026 Anemia, Sickle Cell BCL11A gene canakinumab Casgevy Clustered Regularly Interspaced Short Palindromic Repeats crizanlizumab Fetal Hemoglobin gene therapy hydroxyurea inclacumab Lyfgenia mitapivat voxelotor +
Agios Pharmaceuticals Secures FDA Approval for Aqvesme (Mitapivat) in Thalassemia Treatment on January 02, 2026 Agios Pharmaceuticals Anemia Approved Aqvesme mitapivat Thalassemia United States Food and Drug Administration +
Agios' Sickle Cell Trial Falls Short as Mitapivat Fails to Significantly Reduce Pain Crises on November 20, 2025 Agios Anemia, Sickle Cell Clinical Trials hemoglobin response mitapivat pain crises PYRUKYND Rise Up trial +